A technology which uses Micro RNA (miRNA) inhibition for the treatment of diseases is offered. MiRNA maturation is inhibited by a specifically reduced dicer activity. Thus miRNA production is reduced and consequently the pathogenic impact.
Weitere Informationen: PDF
ipal GmbH
Tel.: +49 (0)30/2125-4820
Ansprechpartner
Ursula Haufe
